Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-1085EL vs Latanoprost in Glaucoma or Ocular Hypertension
NCT02105272Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Carteolol, latanoprost ophthalmic solution 0.005% (TearClear TC-002) in Glaucoma, ocular hypertension, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Apr 2014; status: completed.
02
Drugs
Carteolollatanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02105272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105272.